**Abstract**

**Background:** Brexpiprazole is the newly approved atypical antipsychotics for the adjunctive therapy to antidepressant treatment in major depressive disorder. Brexpiprazole is serotonin-dopamine activity modulator with dopaminergic partial agonist activity like aripiprazole but has lower affinity to D2 and higher affinity to 5-HT1A and 5-HT2A. These pharmacodynamic differences make expectation of lower akathisia and distinct characteristic on management of depression. This systematic review and meta-analysis aimed to evaluate the efficacy and tolerability of brexpiprazole in adjunctive use in depression.

**Methods**: Article searching was performed in PubMed, Cochrane library database, EMbase, Google scholar and Clinicaltrials.gov.(searching was limited to completed studies) from inception to January 14th 2016, using search terms: \"depression\" or \"depressive (for including depressive illness or major depressive disorder)\" and \"brexpiprazole\" or \"OPC-34712\". Statistical analysis for acquiring heterogeiniety of studies and pooled value were performed using RevMan 5.3.

**Results:** 2 journal articles and 13 conference abstracts relevant with 9 completed clinical trials were found. Among 2 more registered completed trials, one had results on online but the other had not. 4 randomised controlled trials used for meta-analysis of brexpiprazole 1∼3mg and yielded superior efficacy to placebo with pooled mean difference of change in MADRS and HAM_D (-1.89, 95% CI= -2.59 ∼ -1.18, p-value\<0.00001; -2.13, 95% CI=-3.28∼0.99, p-value=0.0003). The risk of akathisia and weight increased was higher in brexpiprazole 1∼3mg with risk ratio, 3.39 (95% CI= 2.08 ∼ 5.51) and 4.36 (95%CI= 2.45∼7.77) respectively.

**Conclusion:** Overall, brexpiprazole shows good efficacy and safety profile in adjunctvie treatment for depression.
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